Lenalidomide: What is the right dose in CLL?

Blood

Volumn 111, Issue 11, 2008, Pages 5268-

  Lin, Thomas S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYTOKINE; FLUDARABINE; INTERLEUKIN 6; LENALIDOMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW TOXICITY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MUCORMYCOSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NOTE; OPTIMAL DRUG DOSE; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 78650760117     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-146878     Document Type: Note

References (4)

1. Richardson PG, Schlossman RL, Weller E, et al Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
2. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome Sq deletion. N Engl J Med. 2006;355:1456-1465.
3. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
4. Anderson KC. Lenalidomide and thalidomide: Mechanisms of action-similarities and differences. Semin Hematol. 2005;42(4 Suppl 4):S3-S8.